Test drug PAT in adults with solid tumors
Part of Cancer clinical trials.
This Phase 1 study tests PAT in adults with solid tumor cancers who meet specific immune and health criteria. Because it’s an early safety-and-dosing study, it may help researchers learn whether PAT can be given safely and whether it shows any cancer activity in the right patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be positive for both CMV and EBV blood tests (seropositive).
- Your tumor immune markers must include at least one HLA-A*02:01 type (checked on blood or prior tumor testing).
- You must be 18 or older, and able to do normal daily activity (ECOG 0 or 1).
- Your heart and lungs must be in good enough shape (NYHA heart class I; oxygen level at least 90% on room air).
- You must have recovered from past cancer treatment side effects to mild or less (CTCAE grade 1 or lower).
- You must not be pregnant or breastfeeding, and you must use very effective birth control if you can get pregnant or have a partner who can.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (tumor polypeptide DC-CTL) for adults with solid tumors such as colorectal, lung, or breast cancer. The goal is to see if infusing your own immune cells trained to attack cancer can help control the disease.
This trial tests a new drug, PTT-936, alone or with other treatments, for people with solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
Hear when a new Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.